Free Trial
NASDAQ:INBX

Inhibrx Biosciences (INBX) Stock Price, News & Analysis

Inhibrx Biosciences logo
$25.28 +1.12 (+4.63%)
As of 10:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Inhibrx Biosciences Stock (NASDAQ:INBX)

Key Stats

Today's Range
$24.00
$25.41
50-Day Range
$14.27
$24.57
52-Week Range
$10.81
$25.41
Volume
13,389 shs
Average Volume
105,031 shs
Market Capitalization
$366.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Inhibrx Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

INBX MarketRank™: 

Inhibrx Biosciences scored higher than 38% of companies evaluated by MarketBeat, and ranked 704th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Inhibrx Biosciences are expected to decrease in the coming year, from $104.88 to ($12.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inhibrx Biosciences is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inhibrx Biosciences is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inhibrx Biosciences has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.86% of the float of Inhibrx Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibrx Biosciences has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Inhibrx Biosciences has recently decreased by 24.67%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Inhibrx Biosciences does not currently pay a dividend.

  • Dividend Growth

    Inhibrx Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.86% of the float of Inhibrx Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibrx Biosciences has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Inhibrx Biosciences has recently decreased by 24.67%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Inhibrx Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Inhibrx Biosciences this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for INBX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Inhibrx Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.09% of the stock of Inhibrx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Inhibrx Biosciences' insider trading history.
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

INBX Stock News Headlines

New law could create $3.7 trillion tsunami.
During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.tc pixel
Inhibrx Reports Second Quarter 2025 Financial Results
See More Headlines

INBX Stock Analysis - Frequently Asked Questions

Inhibrx Biosciences' stock was trading at $15.40 at the beginning of the year. Since then, INBX shares have increased by 56.9% and is now trading at $24.16.

Inhibrx Biosciences, Inc. (NASDAQ:INBX) issued its quarterly earnings results on Wednesday, August, 13th. The company reported ($1.85) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $1.07. The company had revenue of $1.30 million for the quarter.

Inhibrx Biosciences (INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

Top institutional shareholders of Inhibrx Biosciences include Perceptive Advisors LLC (6.75%), Sofinnova Investments Inc. (4.89%), Geode Capital Management LLC (1.56%) and Kennedy Capital Management LLC (1.22%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Global Investors Lp Viking, Jon Faiz Kayyem and Kristiina Md Vuori.
View institutional ownership trends
.

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Shopify (SHOP), Zoom Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA).

Company Calendar

Last Earnings
8/13/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INBX
CIK
1739614
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($10.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
0.23
P/E Growth
N/A
Net Income
$1.69 billion
Net Margins
N/A
Pretax Margin
-11,692.29%
Return on Equity
-137.83%
Return on Assets
-76.31%

Debt

Debt-to-Equity Ratio
1.45
Current Ratio
4.98
Quick Ratio
4.98

Sales & Book Value

Annual Sales
$200 thousand
Price / Sales
1,749.18
Cash Flow
$115.05 per share
Price / Cash Flow
0.21
Book Value
$4.73 per share
Price / Book
5.11

Miscellaneous

Outstanding Shares
14,480,000
Free Float
12,010,000
Market Cap
$349.84 million
Optionable
Optionable
Beta
0.24

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:INBX) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners